Cargando…
Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization
Poor water solubility is one of the major challenges to the development of oral dosage forms containing active pharmaceutical ingredients (APIs). Polymorphism in APIs leads to crystals with different surface wettabilities and free energies, which can lead to different dissolution properties. Crystal...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589131/ https://www.ncbi.nlm.nih.gov/pubmed/33092148 http://dx.doi.org/10.3390/pharmaceutics12100995 |
_version_ | 1783600508021243904 |
---|---|
author | Banerjee, Manali Brettmann, Blair |
author_facet | Banerjee, Manali Brettmann, Blair |
author_sort | Banerjee, Manali |
collection | PubMed |
description | Poor water solubility is one of the major challenges to the development of oral dosage forms containing active pharmaceutical ingredients (APIs). Polymorphism in APIs leads to crystals with different surface wettabilities and free energies, which can lead to different dissolution properties. Crystal size and habit further contribute to this variability. An important focus in pharmaceutical research has been on controlling the drug form to improve the solubility and thus bioavailability of APIs. In this regard, heterogeneous crystallization on surfaces and crystallization under confinement have become prominent forms of controlling polymorphism and drug crystal size and habits; however there has not been a thorough review into the emerging field of combining these approaches to control crystallization. This tutorial-style review addresses the major advances that have been made in controlling API forms using combined crystallization methods. By designing templates that not only control the surface functionality but also enable confinement of particles within a porous structure, these combined systems have the potential to provide better control over drug polymorph formation and crystal size and habit. This review further provides a perspective on the future of using a combined crystallization approach and suggests that combining surface templating with confinement provides the advantage of both techniques to rationally design systems for API nucleation. |
format | Online Article Text |
id | pubmed-7589131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75891312020-10-29 Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization Banerjee, Manali Brettmann, Blair Pharmaceutics Review Poor water solubility is one of the major challenges to the development of oral dosage forms containing active pharmaceutical ingredients (APIs). Polymorphism in APIs leads to crystals with different surface wettabilities and free energies, which can lead to different dissolution properties. Crystal size and habit further contribute to this variability. An important focus in pharmaceutical research has been on controlling the drug form to improve the solubility and thus bioavailability of APIs. In this regard, heterogeneous crystallization on surfaces and crystallization under confinement have become prominent forms of controlling polymorphism and drug crystal size and habits; however there has not been a thorough review into the emerging field of combining these approaches to control crystallization. This tutorial-style review addresses the major advances that have been made in controlling API forms using combined crystallization methods. By designing templates that not only control the surface functionality but also enable confinement of particles within a porous structure, these combined systems have the potential to provide better control over drug polymorph formation and crystal size and habit. This review further provides a perspective on the future of using a combined crystallization approach and suggests that combining surface templating with confinement provides the advantage of both techniques to rationally design systems for API nucleation. MDPI 2020-10-20 /pmc/articles/PMC7589131/ /pubmed/33092148 http://dx.doi.org/10.3390/pharmaceutics12100995 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Banerjee, Manali Brettmann, Blair Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization |
title | Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization |
title_full | Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization |
title_fullStr | Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization |
title_full_unstemmed | Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization |
title_short | Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization |
title_sort | combining surface templating and confinement for controlling pharmaceutical crystallization |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589131/ https://www.ncbi.nlm.nih.gov/pubmed/33092148 http://dx.doi.org/10.3390/pharmaceutics12100995 |
work_keys_str_mv | AT banerjeemanali combiningsurfacetemplatingandconfinementforcontrollingpharmaceuticalcrystallization AT brettmannblair combiningsurfacetemplatingandconfinementforcontrollingpharmaceuticalcrystallization |